Skip to main content
Article thumbnail
Location of Repository

Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer

By Hongjiang Wang, Guang Tan, Lei Dong, Lei Cheng, Kejun Li, Zhongyu Wang and Haifeng Luo
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3327688
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2011). A miR-125b binding site polymorphism in bone morphogenetic protein membrane receptor type IB gene and prostate cancer risk in China. Mol Biol Rep.
    2. (2010). A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer.
    3. (2002). activation and is involved in resistance to taxol-induced apoptosis.
    4. (2007). An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells.
    5. (2003). Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
    6. (2009). Cancer statistics,
    7. (2011). Cell-free nucleic acids as biomarkers in cancer patients.
    8. (2011). Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer.
    9. (2010). Characterization of microRNA-125b expression in MCF7 breast cancer cells by ATR-FTIR spectroscopy.
    10. (2011). Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis.
    11. (2011). Circulating MicroRNAs: Potential Biomarkers for Cancer.
    12. (2011). Circulating microRNAs: promising breast cancer Biomarkers.
    13. (2005). Combinatorial microRNA target predictions.
    14. (2009). Computational challenges in miRNA target predictions: to be or not to be a true target?
    15. (2007). Coordinate suppression of ERBB2 and ERBB3 by enforced expression of microRNA miR-125a or miR-125b.
    16. (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction.
    17. (2009). DIANA-microT web server: elucidating microRNA functions through target prediction.
    18. (2009). Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.
    19. (2008). E2F – at the crossroads of life and death.
    20. (2010). E2F3 is a mediator of DNA damage-induced apoptosis.
    21. (2008). Evaluation of biological pathways involved in chemotherapy response in breast cancer.
    22. (2011). Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.
    23. (2011). Intracellular and extracellular microRNAs in breast cancer.
    24. (2008). Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.
    25. (2011). Killing the second messenger: targeting loss of cell cycle control inendocrine resistant breast cancer.
    26. (2007). Life and death decisions by the E2F transcription factors.
    27. (2007). MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.
    28. (2005). MicroRNA gene expression deregulation in human breast cancer.
    29. (2011). MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat.
    30. (2007). MicroRNA signatures in human ovarian cancer.
    31. (2010). MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of proapoptotic Bcl-2 antagonist killer 1 (Bak1) expression.
    32. (2009). MicroRNA-125b is a novel negative regulator of p53.
    33. (2010). MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3’ untranslated region.
    34. (2010). MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer.
    35. (2008). MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.
    36. (2009). MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf.
    37. (2011). miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer.
    38. (2009). miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis.
    39. (2009). MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31.
    40. (2009). Most mammalian mRNAs are conserved targets of microRNAs.
    41. (2011). mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.
    42. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer,
    43. (2003). Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    44. (2006). Oncomirs – microRNAs with a role in cancer.
    45. (2007). OncomiRs: the discovery and progress of microRNAs in cancers.
    46. (1995). PEBA regimen (cisplatin, etoposide, bleomycin, and adriamycin) in the treatment of drug-resistant choriocarcinoma.
    47. (2011). Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR199a/b in solid cancer.
    48. (2011). Reversed urban-rural differences in breast cancer mortality
    49. (2003). RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
    50. (2010). Role of miR-10b in breast cancer metastasis.
    51. (2007). Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.
    52. (2004). Specificity of microRNA target selection in translational repression.
    53. (2003). TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.